乳腺癌肝转移手术后的预后因素 - 19 年的经验。
Prognostic Factors After Surgical Treatment of Liver Metastases from Breast Cancer - 19 Years of Experience.
机构信息
Department of Surgery, Faculty of Medicine in Pilsen, Charles University and University Hospital, Pilsen, Czech Republic.
Department of Pathology, Faculty of Medicine in Pilsen, Charles University and University Hospital, Pilsen, Czech Republic.
出版信息
In Vivo. 2021 Jan-Feb;35(1):417-422. doi: 10.21873/invivo.12273.
BACKGROUND/AIM: The aim of this study was to determine the importance of surgical treatment, utility of hormone receptor status and selected biomarkers in the prognosis of patients with liver metastases from breast cancer (BCLM).
PATIENTS AND METHODS
Thirty female underwent surgery for BCLM between 1/2000 and 1/2019.
RESULTS
The type of surgery (resection/radiofrequency ablation) had no impact on overall survival (OS) - (p=0.894). Having more than one BCLM (p=0.003), expression of human epidermal receptor 2 in metastases (p=0.034), as well as an elevated presurgical level of carbohydrate antigen 19-9 (p=0.017) and postsurgical thymidine kinase (p=0.034) were negative prognostics factor for recurrence-free survival. The factors affecting OS included the number of liver procedures (p=0.021), the degree of proliferative activity (p=0.008) and elevated postsurgical carcinoembryonic antigen level (p=0.038).
CONCLUSION
The type of surgery had no impact on OS. Markers and hormonal status of liver metastases are important factors affecting prognosis.
背景/目的：本研究旨在确定手术治疗、激素受体状态和选定生物标志物在乳腺癌肝转移（BCLM）患者预后中的重要性。
患者与方法
2000 年 1 月至 2019 年 1 月期间，有 30 名女性接受了 BCLM 的手术治疗。
结果
手术类型（切除/射频消融）对总生存期（OS）无影响（p=0.894）。有多个 BCLM（p=0.003）、转移中人表皮受体 2 的表达（p=0.034）以及术前碳水化合物抗原 19-9 水平升高（p=0.017）和术后胸苷激酶（p=0.034）是无复发生存的负预后因素。影响 OS 的因素包括肝脏手术次数（p=0.021）、增殖活性程度（p=0.008）和术后癌胚抗原水平升高（p=0.038）。
结论
手术类型对 OS 无影响。肝转移的标志物和激素状态是影响预后的重要因素。
Zotero 插件